Seeking Alpha

Celgene (CELG) has paid $15M for the right to first negotiation for the Neo-Kidney Augment...

Celgene (CELG) has paid $15M for the right to first negotiation for the Neo-Kidney Augment product of closely held Tengion. The product is in Phase I trials and is designed to restore renal function in patients with chronic kidney disease. Celgene has also obtained an exclusive option to acquire assets such as Tengion's technology for growing esophageal implants, and it has received stock warrants. Celgene invested $5M in Tengion in October 2012. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs